Go to the 8th Feb 2017 release whereby the CE Mark is granted provided that the company undertake a provision of supplemental data from 20 locally advanced pancreatic cancer patients supporting existing safety and clinical performance data already reviewed and Oncosil medical agrees to undertake a post marketing clinical follow up programme.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.18 |
Change
0.160(15.7%) |
Mkt cap ! $16.78M | |||
| Open | High | Low | Value | Volume |
| $1.05 | $1.18 | $1.03 | $37.33K | 34.98K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 13759 | $1.13 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.18 | 4587 | 1 |
View Market Depth
| Last trade - 13.22pm 26/06/2025 (20 minute delay) ? |
| OSL (ASX) Chart |